| Literature DB >> 34936397 |
Megan Jehn1, Urvashi Pandit1, Susanna Sabin1, Camila Tompkins1, Jessica White1, Erin Kaleta1, Ariella P Dale1, Heather M Ross1, J Mac McCullough1, Susan Pepin1, Katherine Kenny1, Heidi Sanborn1, Natalie Heywood1, Amy H Schnall1, Timothy Lant1, Rebecca Sunenshine1.
Abstract
We conducted a community seroprevalence survey in Arizona, from September 12 to October 1, 2020, to determine the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the seroprevalence estimate to predict SARS-CoV-2 infections in the jurisdiction by applying the adjusted seroprevalence to the county's population. The estimated community seroprevalence of SARS-CoV-2 infections was 4.3 times greater (95% confidence interval = 2.2, 7.5) than the number of reported cases. Field surveys with representative sampling provide data that may help fill in gaps in traditional public health reporting. (Am J Public Health. 2022;112(1):38-42. https://doi.org/10.2105/AJPH.2021.306568).Entities:
Mesh:
Substances:
Year: 2022 PMID: 34936397 PMCID: PMC8713634 DOI: 10.2105/AJPH.2021.306568
Source DB: PubMed Journal: Am J Public Health ISSN: 0090-0036 Impact factor: 9.308